Lacutamab is under clinical development by Innate Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lacutamab’s likelihood of approval (LoA) and phase transition for Anaplastic Large Cell Lymphoma (ALCL) took place on 01 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 01 Jun 2021 decreased Lacutamab’s Phase Transition Success Rate (PTSR) for Cutaneous T-Cell Lymphoma, decreased LoA and PTSR for Sezary Syndrome, and decreased PTSR for Transformed Mycosis Fungoides.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lacutamab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lacutamab overview

Lacutamab (IPH-4102) is under development for the treatment of relapsed and refractory sezary syndrome (SS),cutaneous T-cell lymphomas such as transformed mycosis fungoides (TMF),and relapsed and refractory including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), follicular T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, adult T-cell leukemia/lymphoma (ATL), hepatosplenic T-cell lymphoma (HSTL), enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and aggressive NK-cell leukemia (ANKL). It was administered intravenously. The drug candidate is a cytotoxic antibody against KIR3DL2-expressing cancers.

Innate Pharma overview

Innate Pharma is a biotechnology company that develops antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory (r/r) hairy cell leukemia. The company is investigating Lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody for cutaneous T-cell lymphoma (CTCL); Monalizumab, an immune checkpoint inhibitor targeting solid tumors, head and neck cancer, and Avdoralimab antibody against bullous pemphigoid. Innate Pharma is also evaluating IPH5201, IPH5301, IPH6101 and IPH62 antibodies for the treatment of various of tumors. It works in partnership with Sanofi SA, AstraZeneca Plc and other biopharmaceutical companies to develop its products. Innate Pharma is headquartered in Marseille, Provence Alpes Cote d’Azur, France.

Quick View Lacutamab LOA Data

Report Segments
  • Innovator
Drug Name
  • Lacutamab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Innate Pharma
  • Originator: University of Genoa
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.